title: Zero-Order Controlled Delivery of Gliclazide from Polyethylene Oxides Matrix Tables: In vitro and In vivo Evaluation.
abstract: BACKGROUND
  In recent years, controlled and sustained release drug delivery system has become the focus of pharmaceutical researchers. Some technologies aimed to develop the controlled and sustained release of the drug, which used to be administered several times a day and generate plasma concentration fluctuation. As all, a controlled drug release rate has always been a goal pursued by researchers. This paper introduced a controlled delivery hydrophilic matrix system, and evaluated their relevance between in vitro and in vivo behaviors.
  
  
  METHODS
  The matrix tablets were fabricated by direct powder compression method. Single-factor test and the orthogonal experimental design were used to find out the optimal formulation. And the in vivo pharmacokinetics study was also evaluated in this paper.
  
  
  RESULTS
  The amount of WSR N301 and low viscosity materials significantly affect the drug release. Compared with commercially available sustained-release tablets Diamicron®, the pharmacokinetics parameters of these matrix tablets exhibited similar blood profiles, and other parameters such as prolonged Tmax, Cmax, MRT and similar bioavailability. However, this matrix system showed unstable blood profiles in comparison with two-layer-core osmotic pump tablet. The IVIVC study suggested that there was a good correlation between absorption in vivo and drug release in vitro.
  
  
  CONCLUSIONS
  Zero-order controlled drug release of hydrophilic matrix system has the simpler manufacture process. And it will be a promising system to control drug release. Due to the disadvantage of hydrophilic matrix tablets in vivo release, for further research the zero-order delivery of PEO matrix tablets system, some pharmaceutical technology are needed to decrease the influence of gastrointestinal peristalsis. Therefore, the study of polyethylene oxide hydrophilic matrix tablets provides a promising formulation for promoting the development of a drug delivery system.
authors.forename: Lijie
authors.initials: L
authors.lastname: Wang
authors.affiliation: Shenyang Pharmaceutical University, No.103, Wenhua Road, Shenyang 110016, China.
authors.forename: Xinggang
authors.initials: X
authors.lastname: Yang
authors.forename: Yan
authors.initials: Y
authors.lastname: Di
authors.forename: Kai
authors.initials: K
authors.lastname: Chen
authors.forename: Haoyang
authors.initials: H
authors.lastname: Wen
authors.forename: Weisan
authors.initials: W
authors.lastname: Pan
mesh_terms: D000818:Animals; D004285:Dogs; D016503:Drug Delivery Systems; D005907:Gliclazide / Q000008:administration & dosage* / Q000737:chemistry / Q000493:pharmacokinetics; D057927:Hydrophobic and Hydrophilic Interactions; D007004:Hypoglycemic Agents / Q000008:administration & dosage* / Q000737:chemistry / Q000493:pharmacokinetics; D011092:Polyethylene Glycols / Q000737:chemistry*; D013607:Tablets
chemical_list: D007004:Hypoglycemic Agents; D013607:Tablets; D011092:Polyethylene Glycols; D005907:Gliclazide
keywords: Hydrophilic matrix tablets; IVIVC; in vitro; pharmacokinetic; zero-order